Top Stories
The newly launched biotech said its bispecific BLVD101 could extend dosing well beyond Vera's weekly Trutakna and Vertex's monthly povetacicept.
The startup plans to extend its model of pairing prescription medicines with therapeutic software to other disease areas.
The latest win comes in first-line squamous non–small-cell lung cancer, with the FDA's decision for the PD-1/VEGF bispecific due this fall.
Silence raised $175 million in an upsized offering, while AbCellera is looking to bag $200 million.
The Chinese biotech is developing a small-molecule eye drop for retinal diseases, as well as a second-generation menin inhibitor for leukaemia.
Conference News
NEW YORK and SUZHOU, China, Aug. 13, 2026 /PRNewswire/ -- Accro Bioscience, a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today ...
A number of key opinion leaders (KOLs) told FirstWord that Ziihera could quickly replace trastuzumab in this setting.
– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –– KOMZIFTI® achieved majority share of new patient sta...
Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved ...
BridgeBio Pharma is lying in wait to capitalise on any weakness at Alnylam Pharmaceuticals, and this month's presentation of the results from the CARDIO-TTRansform trial could provide ample opportunity.
